News Articles and Montana BioScience Alliance Newsletters

MONTANA BIOSCIENCE ENTERPRISES IN THE NEWS

National Institutes of Health — Rocky Mountain Laboratories
|
May 21, 2024

NIAID scientists and colleagues are investigating a potential treatment strategy against Lyme disease that would directly suppress Borrelia burgdorferi, the bacterium that causes the disease. If successful, their idea could reduce or end aggressive broad-spectrum antibiotic treatments that can be drawn-out and destroy the body’s helpful bacteria.

Golden Helix, Inc., a leading provider of clinical bioinformatics solutions, is pleased to announce that it has received CE mark approval for its genetic analysis platform VarSeq Suite. This significant regulatory milestone paves the way for the expansion of Golden Helix’s advanced genetic analytics products to the European market, ensuring compliance with the European Union’s health, safety, and environmental protection standards.

National Institutes of Health — Rocky Mountain Laboratories
|
May 17, 2024

A new study of prion diseases, using a human cerebral organoid model, suggests there is a substantial species barrier preventing transmission of chronic wasting disease (CWD) from cervids—deer, elk and moose—to people.

Inimmune, a leading clinical stage biotech company focused on the development of novel vaccine adjuvants, immunotherapies and delivery systems, has announced the top line results from its Phase 1b Multiple Ascending Dose (MAD) study of INI-2004 in people suffering with Allergic Rhinitis. 

A team at Montana State University published research this week that shows how RNA, the close chemical cousin to DNA, can be edited using CRISPRs. The work reveals a new process in human cells that has potential for treating a wide variety of genetic diseases.  Postdoctoral researchers Artem Nemudryi and Anna Nemudraia conducted the research alongside Blake Wiedenheft, professor in the Department of Microbiology and Cell Biology in MSU’s College of Agriculture. The paper, titled “Repair of CRISPR-guided RNA breaks enables site-specific RNA excision in […]

ARTICLES OF INTEREST

National Institutes of Health
|
October 8, 2023

Updates from product development and small business programs

National Cancer Institute, SBIR Development Center
|
August 30, 2023

Are you working to develop an innovative cancer technology? Take a step forward in your commercialization journey through the newly released FY2024 SBIR Contract Solicitation! This funding opportunity aims to provide early-stage funding to small businesses that are developing cancer technologies in areas defined by the National Cancer Institute.

U.S. Food and Drug Administration
|
July 16, 2023

The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.

National Institutes of Health
|
July 15, 2023

The PHS 2023-2 omnibus solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications have been released. The first application due date is Tuesday, September 5, 2023.

Centers for Disease Control and Prevention
|
June 22, 2023

The panel’s decision moves the U.S. one step closer to making jabs against respiratory syncytial virus available to the public this fall, when the disease typically begins to spread at higher levels.

NEWSLETTER

Newsletter
|
May 7, 2024

View the Spring 2024 Newsletter now!

Newsletter
|
February 20, 2024

View the Winter II 2024 Newsletter now!